Elimusertib
Elimusertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target serine/threonine-protein kinase ATR.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
10 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | C85.9 | 1 | 1 | — | — | — | 1 | |
| Ewing sarcoma | D012512 | EFO_0000173 | 1 | 1 | — | — | — | 1 | |
| Alveolar rhabdomyosarcoma | D018232 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 3 | — | — | — | — | 3 |
| Neoplasms | D009369 | C80 | 3 | — | — | — | — | 3 | |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 2 | — | — | — | — | 2 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | — | — | — | — | 2 |
| Lung neoplasms | D008175 | C34.90 | 2 | — | — | — | — | 2 | |
| Small cell lung carcinoma | D055752 | 2 | — | — | — | — | 2 | ||
| Colorectal neoplasms | D015179 | 1 | — | — | — | — | 1 | ||
| Digestive system neoplasms | D004067 | 1 | — | — | — | — | 1 | ||
| Neuroendocrine carcinoma | D018278 | 1 | — | — | — | — | 1 | ||
| Squamous cell carcinoma of head and neck | D000077195 | 1 | — | — | — | — | 1 |
Show 19 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ELIMUSERTIB |
| INN | elimusertib |
| Description | Elimusertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target serine/threonine-protein kinase ATR. |
| Classification | Small molecule |
| Drug class | serine/threonine kinase inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H]1COCCN1c1cc(-c2ccnn2C)c2ccnc(-c3ccn[nH]3)c2n1 |
Identifiers
| PDB | — |
| CAS-ID | 1876467-74-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4647810 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 7N13IK9LNH (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
ATR
ATR
Organism
Homo sapiens
Gene name
ATR
Gene synonyms
FRP1
NCBI Gene ID
Protein name
serine/threonine-protein kinase ATR
Protein synonyms
Ataxia telangiectasia and Rad3-related protein, FRAP-related protein 1, FRAP-related protein-1, MEC1, mitosis entry checkpoint 1, homolog
Uniprot ID
Mouse ortholog
Atr (245000)
serine/threonine-protein kinase ATR (Q9JKK8)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 54 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more